NCT07460362 2026-03-10
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Peking University Third Hospital
Phase 2 Recruiting
Clinical Trials
32 trialsNCT02390869 2025-12-02
FIL_RENOIR12
Fondazione Italiana Linfomi - ETS
Phase 3 Active not recruiting
NCT07126236 2025-08-17
REPIFIR
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT06651853 2025-07-23
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT03836014 2024-12-06
CONFIRM
Assistance Publique - Hôpitaux de Paris
Phase 3 Active not recruiting
NCT00482261 2024-11-08
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT01199575 2024-08-15
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
University of California, San Diego
Phase 2 Completed
NCT00799513 2024-04-10
RV-NHL-PI351
IRCCS San Raffaele
Phase 2 Completed
NCT02341014 2024-04-04
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT05797948 2023-04-04
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT03302728 2022-05-19
EpiBrentlen
Peter MacCallum Cancer Centre, Australia
Phase 1 Completed
NCT02963610 2021-12-30
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT00981708 2021-04-30
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
University of Athens
Phase 1/2 Completed
NCT01380106 2021-01-25
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Boston VA Research Institute, Inc.
Phase 2 Completed
NCT01956695 2020-12-17
REVRI
Institut Curie
Phase 2 Completed
NCT04329130 2020-04-24
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT01788189 2020-02-26
LeMLAR
University Hospital, Essen
Phase 1/2 Completed
NCT04109872 2020-02-05
Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Unknown
NCT01729104 2019-10-22
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02060656 2019-09-19
LEGEND
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT02075021 2018-10-15
rev/abraxane
NYU Langone Health
Phase 1/2 Terminated
NCT02986451 2018-08-14
Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
Sun Yat-sen University
Phase 2 Withdrawn
NCT02206503 2018-08-02
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
Fondazione EMN Italy Onlus
Phase 2 Completed
NCT00538824 2018-06-06
DexTR
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02983097 2018-01-19
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 1/2 Terminated
NCT01121757 2016-09-12
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Duke University
Phase 2 Terminated
NCT01450215 2016-03-25
Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma
Karolinska University Hospital
Phase 2 Completed
NCT01133665 2014-11-24
Cetuximab and Lenalidomide in Head and Neck
University of Chicago
Phase 2 Completed
NCT00968331 2012-08-27
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
University of Bologna
Phase 2 Terminated
NCT01010243 2012-05-30
MM03
University of Regensburg
Phase 1/2 Unknown
NCT00306813 2009-08-04
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
University of Wuerzburg
Phase 1/2 Completed